MYELOMATCH Screening Trial
A Screening Study to Assign People With Myeloid Cancer to a Treatment Study or Standard of Care Treatment Within myeloMATCH (MyeloMATCH Screening Trial)
This trial is the first step in joining a large research study called myeloMATCH. In myeloMATCH, researchers will conduct many different clinical trials for people with acute myeloid leukemia (AML) or myelodysplastic syndrome (MDS).
This trial is a screening study. It uses biomarker testing to tell the study doctors if they can match
you with a myeloMATCH clinical trial for cancer treatment.
A biomarker (sometimes called a marker) is anything about the body that can be measured. In cancer care, specific proteins, genes, and abnormal changes in genes can be important biomarkers. Testing for certain markers can give doctors more information about each patient’s
cancer and how to treat it.
The biomarker testing you receive in myeloMATCH has been approved only for use in clinical trials. The tests have not been approved yet for general use outside of the myeloMATCH study.Procedure: Allogeneic Hematopoietic Stem Cell Transplantation Drug: Azacitidine Other: Best Practice Procedure: Biopsy Procedure Procedure: Biospecimen Collection Procedure: Bone Marrow Aspiration Procedure: Bone Marrow Biopsy Drug: Busulfan
This trial is set up to find out:
• If you have biomarkers that specific drugs can target in myeloMATCH treatment clinical trials
• How well the process of biomarker testing works to match patients with trials for cancer treatment